Currently diagnosis of many diseases is obligated to detection of several disease specific markers referred to as biomarker. European Medical Agency defines biomarkers as measurable characteristics that reflect physiological, pharmacological progression of a disease. Renal diseases including acute kidney injury, chronic kidney disease, glomerular disease, preeclampsia etc., have a high mortality and morbidity rate and are characterized by the rapid or gradual loss of kidney function resulting into serous clinical implications. The gold standard for diagnosis of renal injury i.e. routine estimation of serum creatinine lack sufficient sensitivity for early detection of injury and are not specific for the site of injury having limited clinical utility. In case of diseases such as acute kidney disease and chronic kidney disease creatinine takes several days to reach the steady state and up to 50 % of the kidney function may be lost before the serum creatinine begins to rise during the kidney injury. Hence, there is an impending need of development of specific biomarker that can detect the renal disorders at the earliest which helps in timely preventive or more effective treatments for management of renal disorders. A number of emerging biomarkers are currently being developed in order to help early diagnose and prevent catastrophic outcomes of various renal disorders in clinical practice. The most promising biomarkers of acute kidney injury (AKI) for clinical use include a plasma panel (NGAL and cystatin C) and a urine panel (NGAL, Il-18 and KIM-1).
The major factors fuelling the need for development of novel renal biomarkers includes increasing prevalence of various kidney disorders, along with growing incidence of other chronic disorders such as diabetes, obesity and hypertension, as these diseases are often associated with the gradual loss of kidney function.
Request Free Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-1731
Renal Biomarker Market: Drivers and Restraints
The incidence of chronic kidney diseases (CKD) is increasing rapidly in aging population. The National Institute of Diabetes and Digestive and Kidney Disease estimates that the prevalence of CKD in people aged 65 and older doubled between 2000 and 2008. CKD continues to be a major cause of lost productivity, physician visits and hospitalizations globally. In addition, factors such as increasing prevalence of diabetes and high blood pressure and cardiovascular disorders also contributes towards the exponential market growth of renal biomarkers in the near future. American kidney Fund, 2012 estimated diabetes as one of the leading cause of kidney failure accounting for 44% of the new cases. Furthermore, increasing investments in research and development will further boost the renal biomarker market growth globally as a large number of renal biomarkers are currently being to assess the safety of new drugs.
However lack of awareness and tight regulations scenario in developing countries is expected to restrain the renal biomarker market growth in the near future.
Renal Biomarker Market: Segmentation
The global renal biomarker market has been classified on the basis of marker type, application, end user and geography.
Based on marker type, the global renal biomarker market is divided into following:
- Blood Urea Nitrogen
- Cystatin C
- Neutrophil Gelatinase-Associated Lipocalin (NGAL)
- Kidney Injury Molecule-1 (KIM-1)
- Retinol Binding Protein (RBP) Alanine-aminopeptidase (Ala-AP)
Based on the diagnostic tests, the global renal biomarker is divided into following:
- Radioimmunoassay (RIA)
- Enzyme Linked Immunosorbent Assay (ELISA)
- Chemiluminescent Enzyme Immunoassay (CLIA)
- Particle-Enhanced Turbidimetric Immunoassay (PETIA)
- Liquid Chromatography-Mass Spectrometry
Based on the end user type, the global renal biomarker is divided into following:
- Research Centers
- Specialty Diagnostic Clinics
Renal Biomarker Market: Overview
Biomarkers are defined to be valuable tools in clinical diagnostics as well as in therapeutic drug discovery and development. In order to improve the care of patients with renal disorders there is a need to develop novel renal biomarkers. However, widespread availability of enabling technologies such as functional genomics and proteomics has also accelerated the rate of novel biomarker discovery for renal diseases globally. Additionally FDA clearance and regulatory approval of revolutionary diagnostic assays are also expected to create the revenue traction in global renal biomarker market in the near future.
Request For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-1731
Renal Biomarker Market: Regional Overview
Region wise, the global wide filed imaging systems market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa.North America leads the global renal biomarker market followed by Europe. Growing prevalence of various renal disorders, growing investment in R & D and increased FDA approvals are expected towards the revenue traction in North America. Worldwide market for renal biomarkers is still evolving and major drug development firms and various companies need to work in close coordination with each other in order to develop unique biomarkers for the management of various renal disorders.
Smart Contact Lens: Key Players
Some of the key players in global wide filed imaging systems market are Abbott Diagnostics, F. Hoffmann-La Roche AG, Beckman Coulter Inc., Siemens Healthcare Diagnostics Inc., Thermo Fisher Scientific Inc., Astute Medical Inc., Alere Inc., bioMérieux SA and Randox Laboratories Ltd.
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,